-- CanSino Biologics (HKG:6185, SHA:688185) widened its attributable loss in the first quarter of 2026 to 40.4 million yuan from 11.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.
Loss per share was 0.16 yuan, compared with 0.05 yuan in the corresponding period of the previous fiscal year.
Operating revenue jumped 39% to 190.3 million yuan from 137.2 million yuan in the year-ago period, amid the company's expanding commercial product portfolio, increasing overseas presence, and robust sales of hte MCV4 vaccine.
The vaccine manufacturer attributed the wider loss to a higher operating cost; a rise in selling, administrative, and R&D expenses; and a lower other income related to government grants and international funding support.